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Background: Elevated MELK expression is featured in multiple tumors and correlated with tumorigenesis and
tumor development. This study is aimed to investigate the mechanisms of MELK-mediated development of
gastric cancer.
Methods: MELK expression levels in human gastric cancer were determined by quantitative-PCR and
immunohistochemistry. The effect of MELK on cell activity was explored by knockdown and overexpression
experiments. Cell growth was measured using the CCK-8 assay. Apoptosis and cell cycle distributions were
analyzed by flow cytometry. Migration and invasion were tested using a transwell migration assay. Cytoskeletal
changes were analyzed by immunofluorescence. To explore the molecular mechanism and effect of MELK on
migration and invasion, Western blotting was used to analyze the FAK/Paxillin pathway and pull down assays
for the activity of small Rho GTPases. In vivo tumorigenicity and peritoneal metastasis experiments were
performed by tumor cell engraftment into nude mice.
Results: MELK mRNA and protein expression were both elevated in human gastric cancer, and this was associated
with chemoresistance to 5-fluorouracil (5-FU). Knockdown of MELK significantly suppressed cell proliferation,
migration and invasion of gastric cancer both in vitro and in vivo, decreased the percentages of cells in the G1/G0
phase and increased those in the G2/M and S phases. Moreover, knockdown of MELK decreased the amount of
actin stress fibers and inhibited RhoA activity. Finally, knockdown of MELK decreased the phosphorylation of the
FAK and paxillin, and prevented gastrin-stimulated FAK/paxillin phosphorylation. By contrast, MELK overexpression
had the opposite effect.
Conclusions: MELK promotes cell migration and invasion via the FAK/Paxillin pathway, and plays an important
role in the occurrence and development of gastric cancer. MELK may be a potential target for treatment against
gastric cancer.
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Gastric cancer (GC) is the fourth most common type of
cancer and the second leading cause of cancer deaths
worldwide [1,2]. At present, treatment of GC involves sur-
gery, radiotherapy, chemotherapy and molecular targeted
therapy [3]. Tumor metastasis and recurrence in patients
with GC are considered to be the most significant* Correspondence: byliu@sjtu.edu.cn
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unless otherwise stated.determinants for treatment failure and mortality [4]. The
mechanisms underlying tumor metastasis are very com-
plex, and appear to involve multiple steps [5,6]. There is
thus an urgent need to identify the molecular constituents
of these mechanisms that could be targeted to improve
the treatment of GC.
Maternal embryonic leucine zipper kinase (MELK), a
member of the sucrose-non-fermenting (SNF1)/AMPK
family of serine-threonine kinases, is a cell cycle de-
pendent protein kinase [7,8]. MELK is conserved across
several species including Xenopus (pEg3) [9], murineThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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functional role in multiple cellular processes such as the
proliferation, cell cycle progression, mitosis, and spliceo-
some assembly [8,11-15]. Molecularly, MELK interacts
with and phosphorylates Ser323 of CDC25B to regulate
G2/M progression [8]. The zinc finger protein ZPR9 can
also be phosphorylated by MELK to enable its trans-
location into the nucleus, where it interacts with B-Myb,
leading to its increased transcriptional activity [16]. Recent
studies also show that MELK is frequently elevated in
multiple human tumors such as prostate cancer [17],
breast cancer [18], glioblastoma multiforme [19] and
medulloblastoma [20], and is correlated with a poor
prognosis [21]. Indeed, MELK has recently emerged
as an oncogene and a biomarker overexpressed in mul-
tiple cancer stem cells [20,22,23], and so is considered a
potential therapeutic target [24,25]. Knockdown of MELK
inhibited proliferation, colony formation and survival of
cancer stem cells [20,26]. In prostate cancers with high
Gleason scores, MELK expression was elevated and its in-
hibition by RNAi detailed putative functions in chromatin
modification, embryonic development, and cell migration
[17]. In breast cancer, MELK has been found to interact
with Bcl-GL through its amino-terminal region and
suppress apoptosis [18]. Study also implied that MELK
was involved in the resistance of colorectal cancer cells to
radiation and 5-FU [27].
The FAK/Paxillin pathway plays an important role in
cell migration and invasion [28]. Upon activation of its
upstream pathways, FAK binds SH2 domains of Src
family kinases, which promotes Src kinase activity through
a conformational change and then activates downstream
signals to regulate cell motility, invasion, survival and
proliferation [29,30]. Activated FAK can phosphorylate
various adaptor proteins such as paxillin, which is a
multidomain protein located in focal adhesion complexes
and connects extracellular matrices to the cytoskeleton
[31,32]. The paxillin signaling hub controls the dynamics
of focal adhesion assembly and disassembly through pro-
tein interactions and phosphorylation events. The FAK/
Paxillin pathway also regulates small Rho GTPases, an
important family of small GTPases [33]. These proteins,
including RhoA, Rac1 and Cdc42, act as molecular
switches that cycle between an active GTP-bound and an
inactive GDP-bound forms, and play important roles in
cytoskeletal reorganization [34]. Paxillin phosphorylation
leads to enhanced Rac1 activity and decreased RhoA activ-
ity [35,36]. In addition, recent studies have indicated that
FAK signaling can promote matrix-degrading invasive
behavior through a pathway involving the c-Jun NH2-
terminal kinase and MMP-mediated pathways [37].
Here we demonstrate that MELK expression is elevated
in tumor-derived primary human gastric tissues compared
to normal controls at both mRNA and protein levels. Thisenhanced expression of MELK is shown to be associated
with pleiotropic effects in gastric cancer cells, including
increased cell proliferation, migration, and invasion. Fi-
nally, we show that MELK can regulate RhoA activity and
promote cell migration and invasion via the FAK/Paxillin
pathway.
Results
MELK is overexpressed in gastric tumor tissues and cell
lines
We evaluated the expression of MELK mRNA in 150
pairs of gastric cancer and non-tumor tissues by qPCR.
As shown in Figure 1A and B, we found higher expression
levels of MELK mRNA in these gastric cancer tissues
compared to non-tumor tissues.
Next we investigated the MELK protein levels in the
human gastric cancer and non-tumor tissues by IHC.
Ninety-eight pairs of tumor and non-tumor gastric tis-
sues were stained, and the MELK protein was found to
be localized in the cytoplasm. The positive rates of
MELK protein detection were 37.7% (23/61) in non-
tumor tissues and 65.4% (51/78) in tumor tissues, which
is significant (Figure 1C and D). Furthermore, statistical
analysis showed that the presence of the MELK protein
was significantly correlated with clinicopathological
parameters. As shown in Table 1, the presence of MELK
was elevated in well differentiated and intestinal type
gastric cancer. We also found that MELK mRNA and
protein were elevated in gastric cancer cell lines com-
pared with the immortalized normal gastric epithelial
cell line GES-1 (Figure 1E). Together, these data clearly
indicate that MELK is overexpressed in gastric cancer
tissues and cell lines.
MELK is associated with resistance of gastric cancer cells
to 5-FU
In order to investigate the relationship between MELK
and chemoresistance to 5FU in gastric cancer cells,
SGC7901 and NCI-N87 cells were exposed to different
concentrations of 5-FU (0, 1, 2, 4, 8, 16 μg/ml), and cells
were then collected after 48 h for qPCR analysis and
Western blotting to determine the MELK expression
level. We found that the expression level of MELK in
these two cell lines significantly increased after 5-FU
treatment (Figure 2A and B). To further explore the
effect of MELK on chemoresistance to 5FU, we used
shRNA to generate MELK-knockdown NCI-N87 cells
(NCI-N87/MELK-shRNA) and used the pL/ERS/GFP
lentivirus vector to generate MELK-overexpressing
SGC7901 cells (SGC7901/MELK). The efficacy of MELK
knockdown and overexpression is shown in Figure 2C
and D. More than 80% of MELK mRNA and protein
was suppressed in the NCI-N87 cells compared with the
negative control (NCI-N87/nc-shRNA) cells, while these
Figure 1 Elevated MELK expression in gastric cancer tissue array and gastric cancer cells. A and B, Elevated expression of MELK mRNA in
150 pairs of gastric cancer tissues was carried out by qPCR. Data is shown as -ΔΔCt and 2-ΔCt (*P < 0.05). C, Expression of MELK was examined by
immunohistochemistry staining in non-tumor gastric tissue, diffuse-type gastric cancer and intestinal-type gastric cancer. Original magnification:
20X and 200X. Scale bars = 200 μm. D, Analysis of MELK protein expression in 61 non-tumor gastric tissues and 78 gastric cancer tissues (**P < 0.01).
E, Expression of MELK in human gastric cancer cell lines and immortalized normal gastric cell line. MELK mRNA and protein levels were examined by
qPCR and immunoblotting. Data are shown as mean ± SD of three independent experiments.
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with the empty vector transfected (SGC7901/vector) cells.
To investigate whether MELK is associated with cell
apoptosis induced by 5-FU, NCI-N87/MELK-shRNA,
SGC7901/MELK, and control cells were treated with dif-
ferent concentrations of 5-FU (0, 2, 4, 8 μg/ml) followed
by analysis for apoptosis. Apoptosis was determined by
flow cytometry (FCM) 48 h after adding 5-FU. Com-
pared with the control group, apoptosis of the MELK-
knockdown group gradually increased in a manner
that correlated with the 5-FU concentration (Figure 2E
and Additional file 1: Figure S1-A). In contrast, apoptosisdecreased proportionally to the 5-FU concentration in the
SGC7901/MELK group (Figure 2F and Additional file 1:
Figure S1-B). These data indicated that MELK could
be associated with resistance of gastric cancer cells
against 5-FU.
MELK is involved in cell proliferation, cell cycle
progression, migration, and invasion
To further investigate the cellular effects of MELK,
we evaluated cell proliferation, cell cycle progression,
migration, and invasion of NCI-N87/MELK-shRNA
and SGC7901/MELK cells. We analyzed cell proliferation
Table 1 Relationship between MELK expression level and
clinicopathologic variables in 78 gastric cancer tissues
Clinicopathologic parameters MELK protein P
−(n = 27) +(n = 51)
Age (years)
≤60 12 23 0.522
>60 15 21
Gender
Male 21 38 0.749
Female 6 13
Tumor size (cm)
≤5 17 33 0.879
>5 10 18
Lauren classification
Intestinal 2 25 <0.001
Diffuse 25 26
Differentiation
Poorly, undifferentiated 25 31 0.003
Well, moderatelly 2 20
Local invasion
T1,T2 6 14 0.615
T3,T4 21 37
Lymph node metastasis
No 3 14 0.096
Yes 24 37
TNM stage
I,II 5 12 0.61
III,IV 22 39
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that the knockdown of MELK reduced cell proliferation
compared to the control cells, and that MELK overexpres-
sion slightly promoted cell proliferation (Additional file 2:
Figure S2-A and S2-B). Next we analyzed the cell cycle
distribution by FCM. The percentage of cells located in
the G2/M and S phase was higher in NCI-N87/MELK-
shRNA than control and parental cells, and the percentage
in the G1/G0 phase was lower (Additional file 2: Figure
S2-C and S2-D). Interestingly, MELK overexpression also
increased cell populations in the G2/M and S phases and
decreased those in the G1/G0 phase (P < 0.05) (Additional
file 2: Figure S2-E and S2-F).
We next examined cell migration and invasive ability
with a transwell migration, transwell invasion, and wound
healing assays. The amount of migrated and invaded cells
in NCI-N87/shRNA group was significantly decreased
compared with the control cells (Figure 3A and B). In
contrast, the SGC-7901/MELK group was moderately in-
creased compared with the control cells (Figure 3C and D).In the wound healing assay, NCI-N87/nc-shRNA cells
nearly closed the wound 72 h after scratching, whereas
NCI-N87/shRNA cells were unable to heal the wound
(Additional file 3: Figure S3-A). The wound areas of the
experimental group and controls were significantly differ-
ent (Additional file 3: Figure S3-C). However, MELK over-
expression promoted SGC7901 wound healing (P < 0.05)
(Additional file 3: Figure S3-B and S3-D). Thus, together,
these results implicate MELK in the regulation of charac-
teristic cellular behaviors found in gastric cancers.
MELK affects cell morphology and the cytoskeleton
We first observed dramatic cell morphological alterations
in cells both MELK knockdown and overexpression.
NCI-N87 cells transfected with MELK-shRNA rendered
smaller size and fewer filopodia (Figure 4A). In contrast,
SGC7901 cells exhibited larger size when MELK was over-
expressed (Additional file 4: Figure S4-A). We then asked
whether MELK expression had an effect on the cytoskel-
eton. To do so, cells were stained for F-actin by Immuno-
fluorescence (IFC). As we expected, we also detected
similar cell morphological alterations (Figure 4B and
Additional file 4: Figure S4-B). In addition, analysis of
the cytoskeleton by confocal microscopy indicated that
MELK knockdown significantly reduced the number of
actin stress fibers and filopodia, while MELK overex-
pression increased the occurrence of actin stress fibers
(Figure 4C and Additional file 4: Figure S4-C).
MELK inhibits RhoA activity
As small Rho-GTPases play important roles in cyto-
skeleton regulation, we next analyzed the effect of MELK
expression on Rho-GTPases (RhoA/Rac1/Cdc42). Rho-
GTPase activities were measured using the Rho GTPases
activation Assay Combo Biochem Kit according to the
manufacturer’s instructions. Knockdown of MELK signifi-
cantly inhibited RhoA activity but had no effect on Rac1
and Cdc42 activity (Figure 4D). In contrast, MELK over-
expression slightly promoted RhoA activity and had no
effect on Rac1 and Cdc42 (Additional file 4: Figure S4-D).
MELK promotes FAK and paxillin phosphorylation
FAK/Paxillin pathway is involved in cell migration and
that paxillin can regulate the activities of Rho-GTPases.
We thus explored whether MELK levels affected the phos-
phorylation levels of FAK/paxillin. As shown in Figure 5A
and B, MELK knockdown significantly inhibited Tyr397,
Tyr576/577, and Tyr925 phosphorylation of FAK and
Tyr118 phosphorylation of paxillin. In contrast, MELK
overexpression enhanced phosphorylation of these pro-
teins. This indicated that MELK might be involved in the
regulation of the FAK/Paxillin pathway as an upstream
molecule. Next we examined whether MELK knockdown
could reverse the up-regulation of phosphorylation caused
Figure 2 MELK is associated with resistance of gastric cancer cells to 5-FU. A and B, Effect of 5-FU on MELK expression level (**P < 0.01).
NCI-N87 and SGC7901 cells were treated with 0, 1, 2, 4, 8, 16 μg/ml of 5-FU, and MELK expression was examined by qPCR and Western blotting
48 h later. C and D, qPCR and immunoblotting analysis of the efficacy of MELK knockdown and overexpression (**P < 0.01). pGPU6/GFP/Neo was
used for shRNA plasmid construction. Plasmids were transfected into gastric cancer cells using Lipofectamine 2000. MELK cDNA ORF was cloned
into pL/ERES/GFP plasmid for lentivirus production. E and F, Effect of MELK knockdown and overexpression on apoptosis induced by 5-FU. Cells
were treated with 0, 2, 4, 8 μg/ml of 5-FU, apoptosis was examined by flow cytometry (*P < 0.05, **P < 0.01).
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target the 3′untranslated region (3′UTR) and coding
sequence region (CDS) of MELK. SGC7901/MELK and
SGC7901/vector cells were transfected with siRNAs and
then analyzed by Western blotting after 48 h. We found
that both MELK siRNAs indeed partially reversed the up-
regulation of Tyr397, Tyr576/577, and Tyr925 phosphor-
ylation of FAK and Tyr 118 phosphorylation of paxillin
(Figure 5C-D and Additional file 5: Figure S5A-5B).
MELK regulates cell migration and invasion via the
FAK/Paxillin pathway
As the aforementioned results showed that MELK
promotes FAK phosphorylation, and it is well known thatFAK is an important regulator of cell migration and inva-
sion, we speculated that MELK could regulate cell migra-
tion and invasion via the FAK/Paxillin pathway. We
treated SGC7901 cells with a FAK inhibitor (10 μM) and
analyzed cell migration and invasion. We found that the
differences between SGC7901/MELK and SGC7901/vec-
tor cells in migration and invasion were significantly
decreased after treatment with the FAK inhibitor (Figure 5E
and Additional file 6: Figure S6; P = 0.001 vs. 0.154 and
P = 0.007 vs. 0.144). This result indicates that the inhib-
ition of FAK can counter-act the up-regulatory effect on
migration and invasion caused by MELK overexpression.
Thus, these data combined indicate that MELK regulates
cell migration and invasion via the FAK/Paxillin pathway.
Figure 3 Effects of MELK knockdown and overexpression on cell migration and invasion in vitro. A and B, NCI-N87 cell migration and
invasion were analyzed by a transwell chamber assay (100X) (*P < 0.05, **P < 0.01). Scale bars = 100 μm. C and D, SGC7901 cell migration and
invasion. These data are shown as mean ± SD of three independent experiments.
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paxillin phosphorylation
Gastrin plays an important role in the development of
multiple tumors and induces FAK and paxillin phosphoryl-
ation, suggesting that this might be a factor of tumor
pathogenesis [38]. We thus examined whether knockdown
of MELK could prevent gastrin-stimulated FAK and paxil-
lin phosphorylation. NCI-N87/MELK-shRNA and NCI-
N87/nc-shRNA cells were treated with gastrin (200 μM)
and cells were collected and analyzed by Western blotting
after 0, 15, 30, 45, and 60 mins. Indeed, Tyr397 phosphor-
ylation of FAK and Tyr118 phosphorylation of paxillin
were gradually increased in NCI-N87/nc-shRNA cells in a
time-dependent manner. However, there was no significant
alteration in NCI-N87/shRNA cells (Figure 5F and G).
These data indicate that MELK prevents gastrin-stimulated
FAK and paxillin phosphorylation.
MELK specific inhibitor OTSSP167 suppresses cell
migration and invasion
OTSSP167, a specific inhibitor of MELK, is recently re-
ported to suppress MELK expression and/or activity [25].
We therefore investigated whether or not pretreatment
with OTSSP167 on SGC7901 cells resulted in a reduction
of cell migration and invasion. We incubated SGC7901,
SGC7901/MELK and SGC7901/vector with different
concentrations of OTSSP167 (0, 0.1, 1 μM) for 1 h or 2 h.MELK expression was measured by immunoblotting.
Interestingly, OTSSP167 slightly reduced expression of
MELK protein in SGC7901 and SGC7901/vector, but sig-
nificantly reduced MELK expression in SGC7901/MELK
(Figure 6A). Next we examined cell migration and invasive
ability. As shown in Figure 6B, OTSSP167 significantly
suppressed cell migration and invasion. Furthermore,
similar to MELK-siRNA, OTSSP167 partially reversed the
up-regulation of Tyr397, Tyr576/577, and Tyr925 phos-
phorylation of FAK and Tyr 118 phosphorylation of paxil-
lin (Figure 6C and D), as well as the up-regulatory effect
on migration and invasion (Figure 6E; P < 0.001 vs. 0.062
and P = 0.002 vs. 0.14) caused by MELK overexpression.
MELK promotes tumor growth, peritoneal spreading and
metastasis in vivo
Finally, we tested whether MELK can regulate tumor
growth and peritoneal spreading and metastasis. NCI-
N87/MELK-shRNA, NCI-N87/nc-shRNA, SGC7901/
MELK and SGC7901/vector cells were subcutaneously or
intraperitoneally injected into the nude mice. We found
that MELK knockdown inhibited tumor growth (Figure 7A).
Tumor weights were less in the NCI-N87/MELK-shRNA
group compared with the NCI-N87/nc-shRNA group
(0.21 ± 0.13 g vs. 1.63 ± 0.39 g, P < 0.01, Figure 7B). Fur-
thermore, the peritoneal nodules were less in the NCI-
N87/MELK-shRNA group compared with the NCI-N87/
Figure 4 Effects of MELK knockdown on the cytoskeleton and small Rho-GTPase activity. A, Images of NCI-N87/MELK-shRNA and control
cells (100X). Scale bars = 200 μm. B, Immunostaining of phalloidin (F-actin) in NCI-N87/MELK-shRNA and control cells (100X). Red: F-actin; Blue:
DAPI. Scale bars = 50 μm. C, Immunostaining of phalloidin (F-actin) and DAPI (nucleus) using confocal microscopy (400X). D, Small Rho-GTPase
activity in NCI-N87/MELK-shRNA and control cells was measured by a Rhotekin-RBD or PAK-PBD pulldown assay. Data shows examples taken from
one of three independent experiments.
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Figure 7C and D). In contrast, MELK overexpression
promoted tumor growth (1.6 ± 0.50 g vs. 0.54 ± 0.14 g,
P < 0.01) and peritoneal spreading and metastasis
(22.3 ± 7.06 vs. 14.9 ± 3.38, P < 0.01, Additional file 7:
Figure S7A-7D). However, the effect of MELK knock-
down on tumor growth and metastasis was more pro-
found than MELK overexpression. We also analyzed theexpression of Ki-67 antigen by IHC, a cellular mark
for proliferation. The number of Ki-67-antigen-posi-
tive cells and staining intensity were significantly
lower in the tumors derived from the NCI-N87/MELK-
shRNA cells compared to the NCI-N87/nc-shRNA cells,
and were slightly higher in the SGC7901/MELK group
compared with the SGC7901/vector control (Figure 7E
and Additional file 7: Figure S7-E). These results suggest
Figure 5 MELK could regulate cell migration and invasion via the FAK/Paxillin pathway. A and B, Effects of MELK on FAK and paxillin
phosphorylation levels. Cellular lysates were analyzed by immunoblotting. C and D, 3′UTR-siRNA of MELK partially reversed the up-regulation of
pY397, pY576/577, and pY925 of FAK, and pY118 of paxillin caused by MELK overexpression. SGC7901/vector and SGC7901/MELK cells were
transfected with 3′UTR-siRNA of MELK using Lipofectamine 2000; cells were collected and immunoblotting was performed 48 h later. E, Effect of
FAK inhibitor (FAK-I) on SGC7901 cell migration and invasion. SGC7901, SGC7901/vector and SGC7901/MELK cells were treated with FAK inhibitor
(10 μM); cell migration and invasion were measured after 2 h. F, Knockdown of MELK prevents gastrin-stimulated FAK and paxillin phosphorylation.
NCI-N87/NC-shRNA and NCI-N87/MELK-shRNA cells were treated with gastrin (200nM) and cells were collected and analyzed by immunoblotting after
0, 15, 30, 45, 60 mins. G, Ratio of phosphorylated to total protein, respectively. (Pax: paxillin).
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and metastasis in vivo.
Discussion
Recent studies have shown that MELK plays an important
role in tumorigenesis and tumor development [8,12,17,24].
However, the exact mechanism has not been established.
Here, we showed that MELK expression was up-regulatedin gastric tumors. MELK knockdown and overexpression
models demonstrated its role in regulating cell prolifera-
tion, cell cycle progression, and chemoresistance to 5FU.
Furthermore, we observed that MELK regulated the activ-
ity of RhoA and promote cell migration and invasion via
the FAK/Paxillin pathway.
Many studies have shown that MELK is highly
expressed in tumors and this expression is correlated with
Figure 6 MELK specific inhibitor OTSSP167 suppresses cell migration and invasion. A, Immunoblotting representing MELK expression in
SGC7901 cell following OTSSP167 treatment for indicated period. In the upper panel, SGC7901 cell were treated with different concentration
(0, 0.1, 1 μM) of OTSSP167 for 1 h and 2 h. In the lower panel, SGC7901/vector and SGC7901/MELK cell were treated with 1 μM OTSSP167 for 2 h.
B, OTSSP167 suppresses SGC7901 cell migration and invasion measured by a transwell chamber assay (**P < 0.01). C and D, OTSSP167 partially
reverses the up-regulation of pY397, pY576/577, and pY925 of FAK, and pY118 of paxillin caused by MELK overexpression. SGC7901/vector and
SGC7901/MELK cells were treated with 1 μM OTSSP167 for indicated period and then were collected and measured by immunoblotting. E, Effect
of OTSSP167 on SGC7901 cell migration and invasion. SGC7901/vector and SGC7901/MELK cells were treated with OTSSP167 (1 μM); cell migration
and invasion were measured after 2 h.
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examined 3600 normal and 1701 cancer tissues by oligo-
nucleotide microarray analysis, including breast, cervix,
colorectal, esophagus, kidney, liver, and ovary cancers
[24]. Although MELK has been the focus of many cancer-
related studies, most of these lacked data related to the
protein level, and few have investigated gastric cancer. We
examined here MELK expression in clinical tissue samples
and cell lines, and found that MELK mRNA and protein
expression were both elevated in tumor tissues. We also
analyzed the correlation between MELK expression
and clinicopathological parameters and found that MELKprotein expression was higher in well differentiated and
intestinal type gastric cancers.
Previous studies also suggested that MELK expression
was elevated in cancer stem cells (CSCs) and could
promote CSCs growth, differentiation and self-renewal
[11,23,39,40]. In agreement with this earlier work, we
found that MELK had wide-spread effects involving
chemoresistance, cell proliferation, migration, invasion
and cytoskeleton regulation in gastric cancer cells. We
speculate that this is owing to the effect of MELK on
gastric CSCs. In particular, knockdown of MELK dra-
matically suppressed tumor growth in vivo, although the
Figure 7 Effects of MELK on tumor growth, peritoneal spreading and metastasis in vivo. A, Photographs of tumors derived from NCI-N87/
nc-shRNA and NCI-N87/MELK-shRNA cells and growth curves of tumors in nude mice (*P < 0.05; n = 5 per group). Tumor diameters were measured
every 5 days. B, Average weights of tumors in nude mice (**P < 0.01). C and D, Effects of MELK knockdown on peritoneal spreading and metastasis
(**P < 0.01; n = 10 per group). Metastatic nodules were obvious in the control group as indicated by the red arrows. E, Representative photographs of
immunohistochemical analysis of Ki-67 antigen and MELK protein in tumors of nude mice (original magnification, 200X).
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the cell cycle, the main reason could be that MELK sup-
pressed the proliferation of gastric CSCs. We also found
that MELK expression was elevated after treatment with
different concentrations of 5-FU, and MELK could regu-
late apoptosis induced by 5-FU. As chemoresistance is
closely correlated with CSCs and MELK is generally
regarded as a marker of CSCs, we propose that MELK
expression might be elevated in gastric CSCs and is
closely related to chemoresistance in gastric cancer. We
also hypothesize that MELK might be a potential target
for chemotherapy, but further study is needed to support
this. Furthermore, it appeared as though the effect of
MELK overexpression was not as dramatic as its knock-
down. This might be due to the already relative high
expression of MELK in gastric cancer. Interestingly,
MELK knockdown and overexpression both resulted in
increased cell populations in the G2/M phase. Several
studies also found these contradictory results [8,24,41].In these, it was suggested to be owing to a delay of G2/
M. In addition, MELK might be necessary for cells to
through a G2/M checkpoint but its expression and activ-
ity are both suppressed once the cell has overcome this
checkpoint.
The migration and invasion of cancer cells involves a
host of processes and the interaction of multiple genes
[42]. Previous studies indicated that MELK plays an im-
portant role in tumors, but the mechanism was unclear.
In this study we found that MELK knockdown or over-
expression decreased or increased Tyr397, Tyr576/577,
and Tyr925 phosphorylation of FAK and Tyr118 phos-
phorylation of paxillin, respectively. The FAK inhibitor
and MELK inhibitor could both partly reverse the up-
regulatory effect on migration and invasion caused by
MELK overexpression. This indicated that MELK could
be an upstream regulator of FAK. Furthermore, we found
that MELK prevented gastrin-stimulated FAK and paxillin
phosphorylation, which may be an important factor for
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MELK in regulating cell migration and invasion via FAK/
Paxillin pathway.
As MELK could regulate the phosphorylation of paxillin,
we also analyzed its effect on the cytoskeleton by IFC. We
found that MELK knockdown decreased the amount of
actin stress fibers and filopodia, while MELK overexpres-
sion resulted in an increase in these structures. We specu-
lated that it might be due to the elevation of Cdc42 and
RhoA activity. The phosphorylation of FAK Tyr397 can
promote Rac1 activity via the Crk/Dock180/ELMO com-
plex [33,43]. Furthermore, phosphorylated Tyr31/Tyr118
of paxillin can bind to p120RasGAP, which releases the
inhibitory interaction of p120RasGAP with p190RhoGAP
and then suppresses RhoA activity [36]. However, we
found that knockdown of MELK inhibited RhoA activity,
whereas its overexpression promoted RhoA activity. In
addition, there was no effect on the activities of Rac1 and
Cdc42, which seemed rather contradictory. Similarly, Zhai
[44] also found that the overexpression of FAK increased
RhoA activity and p190RhoGEF phosphorylation in neur-
onal cells. Our data thus provide additional evidence that
FAK could have both positive and negative effects on
RhoA. Thus, the effect of MELK through RhoA or FAK/
paxillin may affect cell migration and invasion.
In summary, our data indicate that MELK expression
is elevated in gastric cancer. MELK plays an important
role in the regulation of cell proliferation, cell cycle
progression, chemoresistance, migration, invasion, and
cytoskeleton assembly. Furthermore, MELK was found
to promote cell migration and invasion via the FAK/
Paxillin pathway, which could thus be a potential focus of
future therapy against gastric cancer.
Methods
Ethical statement
Written informed consent was obtained from all partici-
pants. The study was approved by the Human Research
Ethics Committee of Ruijin Hospital, School of Medicine,
Shanghai Jiao Tong University (Permit number: HREC
08–028). All animal experiments were approved by the
Laboratory Animal Ethics Committee of Ruijin Hospital
(Permit Number: 2013062) and performed in accordance
with the Guide for the Care and Use Laboratory Animals
of Ruijin Hospital, School of Medicine, Shanghai Jiao
Tong University.
Cell lines and chemicals
Gastric cancer cell lines SGC7901, BGC823, MKN45,
MKN28, NCI-N87, AGS and an immortalized normal
gastric epithelial cell line GES-1 were preserved in the
institute. Cells were cultured in RPMI-1640 medium con-
taining 10% fetal calf serum with 100U/ml penicillin and
100ug/ml streptomycin (GIBCO BRL) and maintained at37°C in a humidified atmosphere of 5% CO2. FAK in-
hibitor and gastrin were from Millipore. MELK inhibitor
OTSSP167 was from MedChem Express.
Tissues
Gastric cancer tissues were obtained from 150 patients
who underwent radical gastrectomy between 2006 and
2008 at the Department of Surgery, Ruijin Hospital,
Shanghai, China. All samples were confirmed by patho-
logical diagnosis. All tissue samples were formalin-fixed
and paraffin-embedded. Eighty pairs of tissue samples
from patients were processed into tissue arrays and con-
firmed by a pathologist.
Plasmids construction and transfection
For MELK knockdown, the target sequence was 5′-
GGATCTCAACCAAGCACATAT-3′, the negative con-
trol sequence was 5′-GTTCTCCGAACGTGTCACGT-3′.
pGPU6/GFP/Neo (GenePharma) was used for shRNA
plasmid construction. Plasmids were transfected into gas-
tric cancer cells using Lipofectamine 2000 (Invitrogen).
For 3′UTR of MELK knockdown, the target sequence was
5′-GCCTACATAAAGACTGTTA-3′, the negative con-
trol sequence was 5′-GTTCTCCGAACGTGTCACGT-3′.
MELK cDNA ORF (Origene Technologies) was cloned
into the pL/ERES/GFP plasmid (Novobio) for lentivirus
production.
qPCR (quantitative-PCR)
Total RNA was isolated using Trizol reagent (Invitrogen)
and cDNA was obtained using a reverse transcription kit
(Promega) according to the manufacturer’s instructions.
qPCR was performed using the Applied Biosystems
7900HT sequence detection system (Applied Biosystems)
and Universal PCR Master Mix (Applied Biosystems).
Relative expression was calculated with GAPDH using
the 2-ΔCt and -ΔΔCt method. The primers for MELK were
5′-CATTAGCCCTGAGAGGCGGTGC-3′ (fwd) and 5′-
GCCCGTCTCTGGCAGAACCCTT-3′ (rev). The primers
for GAPDH were 5′-TTGGCATCGTTGAGGGTCT-3′
(fwd), and 5′-CAGTGGGAACACGGAAAGC-3′ (rev).
Immunohistochemistry staining
Immunohistochemistry (IHC) staining was performed as
previously reported [45]. Polyclonal anti-MELK was used
at a dilution of 1:150 (Sigma). The slides were evaluated
by a single board-certified pathologist (RRT) without
clinicopathologic information. The percentage of positive
cells was divided into five grades (percentage scores): <5%
(0), 5-25% (1), 25-50% (2), 50-75% (3), 75-100% (4). The
intensity of staining was divided into four grades (intensity
scores): no staining (0), weak staining (1), moderate
staining (2) and strong staining (3). MELK staining posi-
tivity was determined by the following formula: overall
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score ≤ 3 was defined as negative, and >3 as positive.Immunoblotting
Cells were lysed using RIPA cell lysis buffer (Kangwei)
supplemented with protease inhibitor cocktail (Cell Sig-
naling Biotechnology). The amount of total protein was
quantified using a protein assay kit (Bio-Rad). Protein
samples were loaded onto 12.5% SDS-PAGE gels and
then transferred onto PVDF membranes. The mem-
branes were blocked in TBS-T buffer containing 5%
non-fat dry milk and hybridized with a primary antibody.
Paxillin (Tyr118) antibody was from Abcam, GAPDH
antibody was from Kangchen Bio-tech, and all other pri-
mary and secondary antibodies were from Cell Signaling
Biotechnology. Finally, membranes were incubated with
HRP-conjugated secondary antibody. Protein bands were
visualized using ECL reagent (Thermo) on a Tanon detec-
tion system.Cell proliferation assay
Cell proliferation was assayed using Cell Counting Kit-8.
Cells were cultured in a 96-well plate at a concentration
of 1 × 104 cells/ml; OD450 was measured 2 h after
adding CCK-8 at 0, 1, 2, 3 and 4 days.Flow cytometry
For cell cycle analysis, cells were harvested and fixed in
70% ice-cold ethanol at 4°C overnight and then incubated
with 100 μg/ml RNase at 37°C for 20 min. After staining
with 50 μg/ml propidium iodide, cell cycle analysis was
performed by fluorescence flow cytometry on a FACScan
machine (Beckman Instruments). For apoptotic analysis,
cells were washed and stained using an Annexin V/PI
double staining kit (BD Biosciences) according to the
manufacturer’s protocol.Cell migration, invasion and wound healing assays
Cell migration and invasion were analyzed using a trans-
well chamber assay (Corning). For migration, cells cul-
tured with serum-free medium were added to the upper
chamber and medium containing 10% fetal calf serum
was added to the lower chamber. For the invasion assay,
insert membranes were coated with diluted Matrigel
(BD Biosciences). After culture, the insert membranes
were fixed and stained with 0.1% Crystal violet. Perme-
ating cells were visualized on an Olympus BX50 micro-
scope (Olympus Opticol Co) and Nikon Digital Sight
DS-U2 (Nikon). For the wound healing assay, cells were
wounded with a pipette tip and then cultured with fresh
DMEM medium containing 1% fetal calf serum. Wound
closing was observed every 24 h.Immunofluorescence staining
Cells were cultured on cover slips for 24 h. The coverslips
were then washed with PBS and fixed in 4% paraformalde-
hyde for 15 min at room temperature. Monolayers were
washed with PBS, then permeabilized with 0.5% Triton
X-100 and blocked with 5% BSA for 1 h. To visualize
the cytoskeleton and nuclei, cells were stained with
rhodamine phalloidin antibody (1:150, Cytoskeleton)
and 4′-6-diamidino-2-phenylindole (DAPI, 0.5 μg/ml).
Images were acquired using an Olympus BX50 micro-
scope (Olympus) and a Zeiss LSM510 confocal micro-
scope (40X oil lens; Carl Zeiss).Rho GTPase assay
Rho GTPases were measured using the Rho GTPases
activation Assay Combo Biochem Kit (Cytoskeleton) ac-
cording to the manufacturer’s instructions. Briefly, cells
were washed with ice cold PBS and then lysed in ice
cold lysis buffer. After quantification of protein con-
centrations, 650 μg of cellular extracts were incubated
with 10 μg Rhotekin-RBD or PAK-PBD affinity beads.
The beads were then pelleted and washed. After add-
ing 2 × Laemmli of sample buffer, GTP-bound RhoA/
Rac1/CDC42 was detected by immunoblotting.In vivo tumorigenesis and metastasis
Male BALB/c nude mice (Institute of Zoology, Chinese
Academy of Sciences) were housed in a specific
pathogen-free (SPF) environment. 1 × 106 cells were
subcutaneously injected into twenty 4-week-old male
nude mice (five mice each group) and 2 × 106 cells
were intraperitoneally injected into forty 5-week-old
male nude mice (ten mice each group). Tumor length
(L) and width (W) were measured every 5 days with
calipers and tumor volume was calculated using the
equation: volume = (W+ L)/2 ×W× L × 0.5236 [46]. Mice
were sacrificed under anesthesia 30 days after injection.
Tumor grafts were fixed, embedded and stained using
MELK and Ki-67 antibody (Dako, dilution 1:50) by IHC.
Furthermore, peritoneal nodules were visualized under
microscope.Statistical analysis
Results were shown as mean ± standard deviation
(SD). Differences in frequency of MELK expression
and the correlation with clinicopathological parame-
ters were analyzed by the Pearsonχ2 test. Differences
between experimental groups were assessed by the
Student’s t test or one-way ANOVA. A two-tailed value
of P < 0.05 was deemed as statistically significant. Sta-
tistical analyses were performed using SPSS 19.0 soft-
ware (SPSS Inc).
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Additional file 1: Figure S1. Effects of MELK knockdown (A) and
overexpression (B) on apoptosis induced by 5-FU. Cells were treated with
0, 2, 4, 8 μg/ml of 5-FU, and apoptosis was examined by flow cytometry.
Additional file 2: Figure S2. Effects of MELK knockdown and
overexpression on cell proliferation and cell cycle progression in vitro. A
and B, Cell proliferation was measured using the CCK-8 assay. MELK
knockdown significantly suppresses NCI-N87 cell proliferation (**P < 0.01)
and MELK overexpression slightly promotes SGC7901 cell proliferation
(*P < 0.05). C, D, E and F, Cell cycle progression was monitored by flow
cytometry (*P < 0.05, **P < 0.01).
Additional file 3: Figure S3. Effects of MELK knockdown and
overexpression on NCI-N87 and SGC7901 cell migration in vitro. A and B,
Cell migratory ability was measured by a wound healing assay. The
wound areas were measured by Image J software. These data are shown
as mean ± SD of three independent experiments. C and D, Analysis of
relative migration (*P < 0.05, **P < 0.01). Scale bars = 200 μm (A) and
1000 μm (B).
Additional file 4: Figure S4. Effects of MELK overexpression on the
cytoskeleton and small Rho-GTPase activity. A, Images of SGC7901/MELK
and control cells (200X). Scale bars = 200 μm. B, Immunostaining of
phalloidin (F-actin) in SGC7901/MELK and control cells (400X). Red:
F-actin; Blue: DAPI. Scale bars = 50 μm. C, Immunostaining of phalloidin
(F-actin) and DAPI (nucleus) using confocal microscopy (400X). D, Small
Rho-GTPase activity in SGC7901/MELK and control cells was measured by
a Rhotekin-RBD or PAK-PBD pulldown assay. Data shows examples taken
from one of three independent experiments.
Additional file 5: Figure S5. MELK-siRNA suppresses FAK and paxillin
phosphorylation. A and B, MELK-siRNA partially reverses the up-regulation
of pY397, pY576/577, and pY925 of FAK, and pY118 of paxillin.
Additional file 6: Figure S6. Effects of FAK inhibitor on SGC7901 cell
migration and invasion. SGC7901, SGC7901/vector and SGC7901/MELK
cells were treated with FAK inhibitor (10 μM); cell migration and invasion
were measured after 2 h. Scale bars = 100 μm.
Additional file 7: Figure S7. Effects of MELK on tumor growth,
peritoneal spreading and metastasis in vivo. A, Photographs of tumors
derived from SGC7901/vector and SGC7901/MELK cells and growth
curves in nude mice (**P < 0.01; n = 5 per group). B, Average weights
of tumors in nude mice (**P < 0.01). C and D, Effects of MELK knockdown
on peritoneal spreading and metastasis (**P < 0.01; n = 10 per group). E,
Representative photographs of immunohistochemical analysis of Ki-67 anti-
gen and MELK protein in tumors of nude mice (original magnification, 200X).
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